Novartis Announced Tafinlar (Dabrafenib) + Mekinist (Trametinib) Significantly Improved Efficacy In Patients Ages 1 To 17 Years Old With Braf V600 Paediatric Low-Grade Glioma (Plgg) Requiring First Systemic Treatment Compared To Chemotherapy, The Current Standard-Of-Care For These Patients. In This Study, Patients Randomized To Receive Tafinlar + Mekinist Experienced A Statistically Significant Overall Response Rate (Orr) Of 47% (Ci: 35-59%) Compared To 11% (Ci: 3-25%, P<0.001) For Those Randomized To Receive Chemotherapy. A New Liquid Formulation Of Tafinlar + Mekinist That Can Be Easier To Administer Than Chemotherapy Was Used In This Trial. The Data Highlighted As Part Of An Official Press Briefing And Oral Presentation At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting (Abstract #Lba2002).
